The natural origins of cytostatic compounds used in rhabdomyosarcoma therapy

Adv Clin Exp Med. 2023 Oct;32(10):1179-1191. doi: 10.17219/acem/161165.

Abstract

Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children and represents a high-grade neoplasm of skeletal myoblast-like cells. About 40% of all registered soft tissue tumors are RMSs. This paper describes our current understanding of the RMS subtypes (alveolar (ARMS), embryonic (ERMS), pleomorphic (PRMS), and spindle cell/sclerosing (s/scRMS)), diagnostic methods, molecular bases, and characteristics. We also present the currently used treatment methods and the potential use of natural substances in the treatment of this type of cancer. Natural cytotoxic substances are compounds that have been the subject of numerous studies and discussions in recent years. Since anti-cancer therapies are often limited by a low therapeutic index and cancer resistance to pharmacotherapy, it is very important to search for new, effective compounds. Additionally, compounds of a natural origin are usually readily available and have a reduced cytotoxicity. Thus, the undiscovered potential of natural anti-cancer compounds makes this field of research a very important area. The introduction of model species into research examining the use of natural cytostatic therapies for RMS will allow for further assessment of the effects of these compounds on cancerous and healthy tissues.

Keywords: anti-cancer therapy; muscle cells; natural compounds; rhabdomyosarcoma.

Publication types

  • Review

MeSH terms

  • Child
  • Cytostatic Agents* / pharmacology
  • Humans
  • Rhabdomyosarcoma* / diagnosis
  • Rhabdomyosarcoma* / drug therapy
  • Rhabdomyosarcoma* / pathology
  • Sarcoma* / pathology
  • Soft Tissue Neoplasms* / pathology

Substances

  • Cytostatic Agents